Transaction details
Adaptive Biotechnologies NASDAQ:ADPT Chief People Officer Francis Lo sold 22,564 shares of common stock on April 8, 2026, for an aggregate amount of approximately $340,039. The per-share sale prices ranged between $14.99 and $15.25. According to a Form 4 filed with the Securities and Exchange Commission, the sales were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that was adopted on September 15, 2025.
Following the disposal of these shares, Lo directly owns 271,154 shares of Adaptive Biotechnologies common stock, the filing shows.
Options exercise on the same day
In addition to the open-market sale, Lo exercised options on April 8, 2026, to acquire 2,344 shares at an exercise price of $3.99 per share, for a total exercise value of $9,352. The filing notes that these options vested incrementally, with vesting beginning on March 4, 2025.
Share price movement
Since the sale, Adaptive Biotechnologies shares have traded lower, most recently at $12.79. That level represents an approximate 14% decline from the price range at which Lo executed the sale, and the stock has fallen about 13.6% over the past week.
Third-party valuation and analysis
InvestingPro analysis, cited in available filings and commentary, indicates the stock currently appears overvalued relative to its Fair Value estimate. The platform also lists nine additional ProTips for ADPT, highlighting topics that include the company’s volatility profile and its profitability outlook.
Company results and analyst responses
Separately from the insider transaction, Adeptus Biotechnologies Corp reported fourth-quarter 2025 financial results that exceeded analyst expectations. The company posted earnings per share of -$0.09 versus a forecast of -$0.18, a 50% positive surprise. Revenue for the quarter was $71.7 million, topping the projected $59.33 million by roughly 20.85%.
Following those results, TD Cowen raised its price target for Adeptus Biotechnologies to $21 while leaving its rating unchanged. BTIG increased its price target to $22, pointing to strong growth in the company’s Minimal Residual Disease (MRD) business, which expanded 54% year-over-year in Q4 and 46% for the full year. Piper Sandler reiterated an Overweight rating, citing the company’s MRD positioning and projecting clonoSEQ volume growth in excess of 30%.
Context and implications
The filings and corporate disclosures show a coordinated set of transactions by a senior executive under a previously adopted trading plan, combined with an options exercise tied to earlier vesting. Market participants will note the juxtaposition of an insider sale and the company’s reported top-line and relative EPS outperformance, alongside third-party commentary that flags valuation and volatility considerations.
Note: This article synthesizes the transaction filing data, public financial results, and available third-party analysis as reported in company disclosures and filings.